These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10751282)

  • 21. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
    Villari V; Rocca P; Fonzo V; Montemagni C; Pandullo P; Bogetto F
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):405-13. PubMed ID: 17900775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A biological basis for the sex bias of antipsychotic drugs adverse events.
    Gurwitz D; Morag A; Oved K
    J Am Geriatr Soc; 2013 Aug; 61(8):1437. PubMed ID: 23937507
    [No Abstract]   [Full Text] [Related]  

  • 25. Neuroleptic malignant syndrome during a change from haloperidol to risperidone.
    Reeves RR; Mack JE; Torres RA
    Ann Pharmacother; 2001 Jun; 35(6):698-701. PubMed ID: 11408988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
    Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN
    Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of relapse in schizophrenia.
    Stalman SL
    N Engl J Med; 2002 May; 346(18):1412-3; author reply 1412-3. PubMed ID: 11987323
    [No Abstract]   [Full Text] [Related]  

  • 29. Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients.
    Sweeney JA; Bauer KS; Keshavan MS; Haas GL; Schooler NR; Kroboth PD
    Neuropsychopharmacology; 1997 Mar; 16(3):217-28. PubMed ID: 9138438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone.
    Mullen B; Brar JS; Vagnucci AH; Ganguli R
    Schizophr Res; 2001 Mar; 48(1):155-8. PubMed ID: 11345946
    [No Abstract]   [Full Text] [Related]  

  • 32. Neuroleptic sensitivity to risperidone in Lewy body dementia.
    McKeith IG; Ballard CG; Harrison RW
    Lancet; 1995 Sep; 346(8976):699. PubMed ID: 7544860
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of novel antipsychotic drugs.
    Raleigh F
    Pharmacotherapy; 1996; 16(6 Pt 2):160S-165S; discussion 166S-168S. PubMed ID: 8948000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroleptic-induced dysphagia: case report and literature review.
    Dziewas R; Warnecke T; Schnabel M; Ritter M; Nabavi DG; Schilling M; Ringelstein EB; Reker T
    Dysphagia; 2007 Jan; 22(1):63-7. PubMed ID: 17024549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
    Apiquian R; Fresán A; Herrera K; Ulloa RE; Lóyzaga C; de la Fuente-Sandoval C; Gutiérrez D; Nicolini H
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):403-8. PubMed ID: 14604455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
    Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
    Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.
    Maust DT; Kim HM; Seyfried LS; Chiang C; Kavanagh J; Schneider LS; Kales HC
    JAMA Psychiatry; 2015 May; 72(5):438-45. PubMed ID: 25786075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study.
    Bo QJ; Li XB; Wang ZM; Li AN; Ma X; Wang CY
    J Clin Psychopharmacol; 2016 Apr; 36(2):125-9. PubMed ID: 26848792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
    Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
    Eur J Clin Pharmacol; 2001 Jul; 57(4):327-31. PubMed ID: 11549212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.